emc易倍官网入口Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • emc易倍官网入口Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • emc易倍官网入口Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • emc易倍官网入口Contacts
    • emc易倍官网入口Our Locations
    • emc易倍官网入口Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • emc易倍官网入口Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • emc易倍官网入口 United States
    • Brazil
    • Canada
    • emc易倍官网入口 Mexico
    • emc易倍官网入口 Australia
    • emc易倍官网入口 China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • emc易倍官网入口 Germany
    • France
    • Nordics
    • Greece
    • Italy
    • emc易倍官网入口 Netherlands
    • Spain
    • Poland
    • emc易倍官网入口 Russia
    • Czech Republic
    • emc易倍官网入口 Switzerland
    • emc易倍官网入口 Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • emc易倍官网入口Clinical Trials
      • Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • emc易倍官网入口Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • emc易倍官网入口Environment
    • emc易倍官网入口Patients
    • People
    • emc易倍官网入口Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • emc易倍官网入口Patients
    • Together for Oncology
    • emc易倍官网入口Together for Rare Disease
    • Together for Neuroscience
    • emc易倍官网入口Collaborate with us
  • Stories
  1. Home
  2. Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€160.20

 €-0.40 (-0.25%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?






2026-05-23 20:58:35